Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05074043
Recruitment Status : Completed
First Posted : October 12, 2021
Last Update Posted : October 12, 2021
Sponsor:
Information provided by (Responsible Party):
Marwa mahmoud Abd El Rady, Assiut University

Brief Summary:

We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19.

All patients with COVID-19 associated Mucormycosis (CAM) admitted to Assuit University Hospital between March 1, 2021, and July 30, 2021, were included in this study. The patient characteristics, the site of mucormycosis, the comorbidities, the steroids usage, and the outcome were analyzed in people with COVID-19.


Condition or disease Intervention/treatment
Mucormycosis Combination Product: antiviral, surgical

Layout table for study information
Study Type : Observational
Actual Enrollment : 433 participants
Observational Model: Case-Crossover
Time Perspective: Retrospective
Official Title: COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
Actual Study Start Date : March 1, 2021
Actual Primary Completion Date : June 30, 2021
Actual Study Completion Date : July 30, 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
covid19
covid 19 proven by clinical, PCR. not associated with mucor
covid19 associated with mucor
covid19 associated with mucor proven by clinical, histopathological
Combination Product: antiviral, surgical
surgical debridment




Primary Outcome Measures :
  1. incidence of covid19 associated mucor [ Time Frame: 3 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Participants with mucormycosis in a confirmed diagnosis of COVID-19
Criteria

Inclusion Criteria:We recruited all cases admitted to Assuit University Hospital for the management of COVID-19 and/or associated complications between March 1, 2021, and July 30, 2021, specifically those with probable mucormycosis based on clinical condition. At various times, internists, intensivists, neurologists, and otolaryngologists were among the specialists who assessed and treated them. Clinical; radiological and histopathological confirmed cases of mucormycosis with coexisting or previous history of COVID-19 were included in this study.

-

Exclusion Criteria:Participants with fungal infections other than mucormycosis or without a confirmed diagnosis of COVID-19 (or serological evidence of preceding COVID-19) were excluded.

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05074043


Locations
Layout table for location information
Egypt
Marwa Abdelrady
Asyut, Egypt, 11711
Sponsors and Collaborators
Assiut University
Layout table for additonal information
Responsible Party: Marwa mahmoud Abd El Rady, lecturer, Assiut University
ClinicalTrials.gov Identifier: NCT05074043    
Other Study ID Numbers: COVID-19 with mucormycosis
First Posted: October 12, 2021    Key Record Dates
Last Update Posted: October 12, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucormycosis
Zygomycosis
Mycoses
Bacterial Infections and Mycoses
Infections
Antiviral Agents
Anti-Infective Agents